A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibodyChad J. Swanson, Jeffrey L. Cummings, Lynn D. Kramer et al.|Alzheimer s Research & Therapy|2021Cited by 818
The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's diseaseMichael S. Rafii, Paul Aisen, Reisa A. Sperling et al.|Alzheimer s & Dementia|2022Cited by 266
Updated safety results from phase 3 lecanemab study in early Alzheimer’s diseaseLawrence S. Honig, Lynn D. Kramer, Marwan N. Sabbagh et al.|Alzheimer s Research & Therapy|2024Cited by 150
Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's diseaseAndrew Satlin, Donald A. Berry, Jinping Wang et al.|Alzheimer s & Dementia Translational Research & Clinical Interventions|2016Cited by 87
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s diseaseShobha Dhadda, Donald A. Berry, Michio Kanekiyo et al.|Alzheimer s Research & Therapy|2022Cited by 37